A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Public ClinicalTrials.gov record NCT02127710. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT02127710
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Interventions
- AZD6094 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 29, 2014
- Primary completion
- Apr 13, 2016
- Completion
- Apr 19, 2020
- Last update posted
- Apr 18, 2021
2014 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35294 | — |
| Research Site | Duarte | California | 91010 | — |
| Research Site | Palo Alto | California | 94305 | — |
| Research Site | Fort Myers | Florida | 33916 | — |
| Research Site | Chicago | Illinois | 60637 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Detroit | Michigan | 48201 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75246 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02127710, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2021 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02127710 live on ClinicalTrials.gov.